ArticleCellular and molecular life sciences : CMLS2014
Antitumoral effects of 9-cis retinoic acid in adrenocortical cancer.
Article in Cellular and molecular life sciences : CMLS, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- The Roles and Clinical Significance of Major Hepatic-Derived Metabolites in Hepatocellular Carcinoma.Journal of gastroenterology and hepatology · 2025Review
- Repurposed Drugs in Gastric Cancer.Molecules (Basel, Switzerland) · 2022Review
- Prolymphangiogenic Effects of 9-Lymphatic research and biology · 2022Article
- Dual effects of 9-cis retinoic acid on ACTH-dependent hyperplastic adrenal tissues.Scientific reports · 2021Article
- Plant Natural Compounds in the Treatment of Adrenocortical Tumors.International journal of endocrinology · 2021Review
- A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence.British journal of cancer · 2020Article
- Association between IL-1R2 polymorphisms and lung cancer risk in the Chinese Han population: A case-control study.Molecular genetics & genomic medicine · 2019Article
- Synergistic effect of co-treatment with all-3 Biotech · 2019Article
- Metabolomics research on potential role for 9-cis-retinoic acid in breast cancer progression.Cancer science · 2018Article
- A case of adrenocortical carcinoma accompanying secondary acute adrenal hypofunction postoperation.World journal of surgical oncology · 2018Article
- Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer.American journal of cancer research · 2016Article
- Transplantation of bovine adrenocortical cells encapsulated in alginate.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy.Cellular and molecular life sciences : CMLS · 2015Review
- Evaluation of 9-cis retinoic acid and mitotane as antitumoral agents in an adrenocortical xenograft model.American journal of cancer research · 2015Article
- Short hairpin RNA (shRNA) of type 2 interleukin-1 receptor (IL1R2) inhibits the proliferation of human osteosarcoma U-2 OS cells.Medical oncology (Northwood, London, England) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The currently available medical treatment options of adrenocortical cancer (ACC) are limited. In our previous meta-analysis of adrenocortical tumor genomics data, ACC was associated with reduced retinoic acid production and retinoid X receptor-mediated signaling. Our objective has been to study the potential antitumoral effects of 9-cis retinoic acid (9-cisRA) on the ACC cell line NCI-H295R and in a xenograft model. Cell proliferation, hormone secretion, and gene expression have been studied in the NCI-H295R cell line. A complex bioinformatics approach involving pathway and network analysis has been performed. Selected genes have been validated by real-time qRT-PCR. Athymic nude mice xenografted with NCI-H295R have been used in a pilot in vivo xenograft model. 9-cisRA significantly decreased cell viability and steroid hormone secretion in a concentration- and time-dependent manner in the NCI-H295R cell line. Four major molecular pathways have been identified by the analysis of gene expression data. Ten genes have been successfully validated involved in: (1) steroid hormone secretion (HSD3B1, HSD3B2), (2) retinoic acid signaling (ABCA1, ABCG1, HMGCR), (3) cell-cycle damage (GADD45A, CCNE2, UHRF1), and the (4) immune response (MAP2K6, IL1R2). 9-cisRA appears to directly regulate the cell cycle by network analysis. 9-cisRA also reduced tumor growth in the in vivo xenograft model. In conclusion, 9-cisRA might represent a promising new candidate in the treatment of hormone-secreting adrenal tumors and adrenocortical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.